Skip to main content

Market Overview

MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals

Share:

In a report published Thursday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $15.00 price target on BioCryst Pharmaceuticals (NASDAQ: BCRX).

In the report, MLV & Co noted, “BioCryst Pharmaceuticals (BCRX) reported significant progress in 2Q14 highlighted by positive results from OPuS-1 and a public offering that netted ~$107MM. Although interest for BCX4430, which has potential utility against Ebola virus disease (EVD), is increasing, we are focused on progress with BCRX's other pipeline assets as drivers of the stock. Specifically, as the OPuS-1 Ph 2a trial of BCX4161 for prophylactic treatment of HAE met all study objectives, BCRX is now poised for BCX4161's advancement into OPuS-2, a Ph 2b trial planned for YE14.

"We also believe the expected dilution (~19%) from raising capital in June removed an overhang on the stock, as we estimate BCRX's $133MM in cash adequate for a significant ramp in its clinical development activities in HAE beyond 2015. We believe the company's momentum going into 2H14 will be positively reflected in BCRX shares. Therefore, we maintain our BUY recommendation and $15 PT.”

BioCryst Pharmaceuticals closed on Wednesday at $13.03.

Latest Ratings for BCRX

DateFirmActionFromTo
Dec 2021OppenheimerInitiates Coverage OnOutperform
Nov 2021RBC CapitalMaintainsSector Perform
Nov 2021BarclaysMaintainsOverweight

View More Analyst Ratings for BCRX

View the Latest Analyst Ratings

 

Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: MLV & Co Vernon T. BernardinoAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com